Key result
COVID-19 vaccine-related ADEM occurred at an older mean age (49 vs 25 years) and mostly after the first dose, whereas myopericarditis mostly developed after the second dose.
Why the study?
Despite the low incidence of complications from COVID-19 vaccines, analyzing post-vaccination myopericarditis and ADEM is important to understand underlying mechanisms and predisposing factors.
Do the age, gender, and dose characteristics differ between post-COVID-19 vaccine ADEM and myopericarditis?
Systematic Review (n=38)
Do the age, gender, and dose characteristics differ between post-COVID-19 vaccine ADEM and myopericarditis?
The differing demographic and dose-related profiles of post-COVID-19 vaccine ADEM and myopericarditis suggest that tissue-specific vulnerabilities, rather than vaccine type, drive these rare complications.
Answers are grounded in this paper and cite their sources.
May inform age- and dose-specific monitoring for ADEM versus myopericarditis; supports distinct tissue vulnerabilities.
Background: COVID-19 vaccines have been a game changer in the pandemic, their extensive use was favorable compared to the burden of COVID-19 complications. Despite the low incidence of complications, it was important to analyze them carefully to understand the underlying mechanisms and predisposing factors. For instance, myopericarditis especially from mRNA vaccines, and its relatively higher prevalence in young adults and adolescents has raised a public concern about the use of this vaccine in this group. We aimed through this review to compare the age likelihood of ADEM from COVID-19 vaccines, with that reported in myopericarditis cases; secondary outcome parameters included the gender and number of doses needed to induce COVID-19 vaccines related ADEM. Methodology: A literature search has been conducted on relevant databases to retrieve all case reports/series and systematic reviews describing ADEM with possible linkage to COVID-19. Exclusion criteria included any report not including the desired outcome parameters. Our results were then qualitatively compared with a similar systematic review reporting myopericarditis from COVID-19 vaccines. Results: In 38 cases with ADEM, mean age was 49±16 compared to 25±14 in myopericarditis, females were more likely to be affected, and while most of myopericarditis cases develop after the second dose, most of ADEM cases develop after the first dose (76%). Moreover, age>56 years was more predictive of negative outcome after ADEM in the form of death or permanent vegetative state. Conclusion: The discrepancy in age, gender and number of doses needed to induce complications between ADEM and myopericarditis, signify that the tissue affected is the major orchestrator of the age, gender, and dose characteristics, and not the type of vaccines. A leakier blood brain barrier with aging, might allow easier passage of autoantibodies and cytokines into the brain while lack of inhibitory immune checkpoints in the myocardium in young age might explain the higher prevalence of those cases in young adults and adolescents.
No takes yet. Share an insight, caveat, or question.
AbdelMassih et al. (2023) conducted a systematic review in Post-COVID-19 ADEM and Myopericarditis (n=38). COVID-19 vaccines vs. Myopericarditis cases was evaluated on Age likelihood of ADEM from COVID-19 vaccines compared with myopericarditis cases. COVID-19 vaccine-related ADEM occurred at an older mean age (49 vs 25 years) and mostly after the first dose, whereas myopericarditis mostly developed after the second dose.
Synapse has enriched 10 related papers. Consider them for comparative context: